Dementia Biomarkers
Cross-source consensus on Dementia Biomarkers from 1 sources and 6 claims.
1 sources · 6 claims
Uses
How it works
Benefits
Comparisons
Evidence quality
Highlighted claims
- Part of ODIN has already contributed to diagnostic cut-offs for cerebrospinal fluid beta-amyloid 1-42, total tau, and phosphorylated tau 181. — ODIN Biobank: a Danish cohort for dementia research- cohort profile
- Alzheimer's disease pathology is defined by amyloid-beta accumulation and hyperphosphorylated tau. — ODIN Biobank: a Danish cohort for dementia research- cohort profile
- ODIN aims to evaluate biomarker associations with clinical and neuroimaging data and compare blood-based with cerebrospinal fluid biomarkers. — ODIN Biobank: a Danish cohort for dementia research- cohort profile
- Biomarkers can help move dementia diagnosis from clinical syndromes toward biologically defined disease categories. — ODIN Biobank: a Danish cohort for dementia research- cohort profile
- Blood-based biomarkers may be cheaper, minimally invasive, and more scalable than imaging and cerebrospinal fluid biomarkers, but they require further validation. — ODIN Biobank: a Danish cohort for dementia research- cohort profile
- Imaging and cerebrospinal fluid biomarkers are considered gold-standard tools, but they are invasive, expensive, and less available outside specialized settings. — ODIN Biobank: a Danish cohort for dementia research- cohort profile